<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03547089</url>
  </required_header>
  <id_info>
    <org_study_id>VI-ISRP-026</org_study_id>
    <nct_id>NCT03547089</nct_id>
  </id_info>
  <brief_title>A Prospective Trial to Assess Breast Cancer Survivors and Vaginal Atrophy Treatment Outcomes</brief_title>
  <acronym>BRAVO</acronym>
  <official_title>A Prospective Trial to Assess Breast Cancer Survivors and Vaginal Atrophy Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>W. Grant Stevens, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marina Plastic Surgery</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The focus of this study is to assess breast cancer survivors perspectives of Viveve速
      Treatment using patient reported outcome tools with a focus on symptoms associated with
      vulvovaginal atrophy/genitourinary syndrome of menopause (GSM). This will be assessed by the
      FSFI, FSDS-R and DIVA questionnaires.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancers that are hormone sensitive require estrogen suppression as a part of
      multimodal treatment. Estrogen suppression also reduces the likelihood of a breast cancer
      recurrence. Therefore, breast cancer survivors with estrogen sensitive tumors are placed on
      hormone suppression therapy with either selective estrogen receptor modulators like tamoxifen
      or aromatase inhibitors like anastrazole. This therapy typically is administered for five
      years after a cancer diagnosis. Regardless of age or pre-existing menopausal status, the
      hormone suppression reduces estrogen levels and can either exacerbate existing menopausal
      symptoms or induce medical menopause in otherwise premenopausal women. This study will
      evaluate the patient's perspective of vaginal therapy using the Viveve速 device in breast
      cancer patients.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Recruitment issues
  </why_stopped>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sexual dysfunction</measure>
    <time_frame>Baseline, 1 month, 3 months, 6 months</time_frame>
    <description>Measurement of changes in sexual dysfunction using the Female Sexual Function Index (FSFI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sexual distress</measure>
    <time_frame>Baseline, 1 month, 3 months, 6 months</time_frame>
    <description>Measurement of changes in sexual distress using the Female Sexual Distress Scale-Revised (FSDS-R)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal symptoms</measure>
    <time_frame>Baseline, 1 month, 3 months, 6 months</time_frame>
    <description>Measurement of changes in vaginal symptoms using the Day-to-Day Impact of Vaginal Aging (DIVA) Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaginal laxity</measure>
    <time_frame>Baseline, 1 month, 3 months, 6 months</time_frame>
    <description>Measurement of changes in vaginal laxity using the Vaginal Laxity Questionnaire (VLQ)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Vaginal Atrophy</condition>
  <condition>Genitourinary System; Disorder, Female</condition>
  <condition>Vaginal Abnormality</condition>
  <condition>Sexual Dysfunction</condition>
  <condition>Sexual Problem</condition>
  <arm_group>
    <arm_group_label>Viveve treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group of women who receive Viveve treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Viveve速</intervention_name>
    <description>A single treatment using Viveve速 with 110 pulses administered to the vaginal introitus at 90 J/cm2</description>
    <arm_group_label>Viveve treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  18 years or older

          -  Breast cancer survivors defined as women with a history of hormone sensitive breast
             cancer on tamoxifen

          -  Self-reported vaginal laxity

          -  Meet diagnosis of sexual dysfunction

          -  Patients must be able to understand and willing to sign a written informed consent
             document and be willing to complete the patient reported outcome tools at the
             scheduled time points

        Exclusion Criteria:

          -  Cognitive impairment

          -  Women currently on chemotherapy and/or radiation or who have had their last
             chemotherapy within 6 months of the intervention

          -  Women with active breast cancer disease

          -  Women currently on hormone therapy or who are pregnant

          -  Women who have had vaginal or pelvic surgery involving the genitalia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W G Stevens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Marina Plastic Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ali A Qureshi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Marina Plastic Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marina Plastic Surgery Associates</name>
      <address>
        <city>Marina Del Rey</city>
        <state>California</state>
        <zip>90292</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 24, 2018</study_first_submitted>
  <study_first_submitted_qc>June 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2018</study_first_posted>
  <last_update_submitted>March 13, 2019</last_update_submitted>
  <last_update_submitted_qc>March 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Marina Plastic Surgery</investigator_affiliation>
    <investigator_full_name>W. Grant Stevens, MD</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

